User profiles for Paolo Bonfanti
 | Paolo BonfantiUniversity of Milano-Bicocca Verified email at unimib.it Cited by 17145 |
High rates of 30-day mortality in patients with cirrhosis and COVID-19
…, A Rimondi, MG Rumi, P Invernizzi, P Bonfanti… - Journal of …, 2020 - Elsevier
Background & Aims Coronavirus disease 2019 (COVID-19) poses a major health threat to
healthy individuals and those with comorbidities, but its impact on patients with cirrhosis is …
healthy individuals and those with comorbidities, but its impact on patients with cirrhosis is …
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
INTRODUCTION Interindividual clinical variability is vast in humans infected with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ranging from silent infection to rapid …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ranging from silent infection to rapid …
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
INTRODUCTION Clinical outcomes of human severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infection range from silent infection to lethal coronavirus disease 2019 (…
2 (SARS-CoV-2) infection range from silent infection to lethal coronavirus disease 2019 (…
Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort …
…, S Mori, G Messinesi, E Contro, P Bonfanti… - The Lancet …, 2020 - thelancet.com
Background The COVID-19 pandemic is challenging advanced health systems, which are
dealing with an overwhelming number of patients in need of intensive care for respiratory …
dealing with an overwhelming number of patients in need of intensive care for respiratory …
Hospital-acquired infections in critically ill patients with COVID-19
Background Few small studies have described hospital-acquired infections (HAIs) occurring
in patients with COVID-19. Research Question What characteristics in critically ill patients …
in patients with COVID-19. Research Question What characteristics in critically ill patients …
[HTML][HTML] An immune-based biomarker signature is associated with mortality in COVID-19 patients
Immune and inflammatory responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
contribute to disease severity of coronavirus disease 2019 (COVID-19). …
contribute to disease severity of coronavirus disease 2019 (COVID-19). …
Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths
…, J Solé-Violán, L Imberti, A Biondi, P Bonfanti… - Science …, 2021 - science.org
Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/ml; in plasma
diluted 1:10) of IFN-α and/or IFN-ω are found in about 10% of patients with critical COVID-19 …
diluted 1:10) of IFN-α and/or IFN-ω are found in about 10% of patients with critical COVID-19 …
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
…, L Imberti, A Biondi, P Bonfanti… - Proceedings of the …, 2022 - National Acad Sciences
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR)
doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing …
doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing …
[HTML][HTML] Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
…, D Ripamonti, F Binda, P Bonfanti… - Journal of translational …, 2020 - Springer
Background Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in
pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients. Methods …
pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients. Methods …
X-linked recessive TLR7 deficiency in~ 1% of men under 60 years old with life-threatening COVID-19
…, T Khan, AN Spaan, CL Dalgard, P Bonfanti… - Science …, 2021 - science.org
Autosomal inborn errors of type I IFN immunity and autoantibodies against these cytokines
underlie at least 10% of critical COVID-19 pneumonia cases. We report very rare, …
underlie at least 10% of critical COVID-19 pneumonia cases. We report very rare, …
